Head-to-head · WeighScore
OrderlyMeds vs Revel RX
By GLP-1 ScorecardUpdated
Score comparison
Revel RX has the higher recorded score — 77.3/100 to 67/100.
Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel Rx advertises the same monthly price across doses and no separate membership fee. Its refund policy still refers to canceling a subscription.
Before you choose
Before comparing the headline prices, the OrderlyMeds review and the Revel RX review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, OrderlyMeds vs TRYM Health and OurView Health vs Revel RX compare each of them with another graded program, and the list of alternatives to OrderlyMeds ranks the programs closest to OrderlyMeds on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | OrderlyMeds | Revel RX |
|---|---|---|
| WeighScore | 67/100 | 77.3/100 |
| Grade | C | C+ |
| Site position | #186 | #48 |
| Semaglutide | $74/mo (starting dose, 2-mo starter plan, new patients only, compounded) | $89/mo (advertised all doses, compounded) |
| Tirzepatide | $299/mo (compounded) | $155/mo (advertised all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
FDAWarning letter issued to OrderlyMeds LLC dba OrderlyMeds in June 2026. See the FDA warning-letter database.
Strengths
- The starter rate and the standing rate are both published, so the step-up is visible before signing up
- No membership fees and no hidden costs, stated as such
- The dose ladder is published: four weeks at 0.25 mg then four weeks at 0.5 mg
- Brand-name routes are priced openly, at retail
What to consider
- The $74 rate is a two-month starter plan billed as $149 up front, and it is open only to patients new to GLP-1 medication; the standing monthly rate is $149
- Tirzepatide has no equivalent standing discount — $299/mo is the ongoing rate
- Brand-name routes are priced at retail: Wegovy $1,839 and Zepbound $1,498
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- FDA issued OrderlyMeds LLC dba OrderlyMeds a warning letter in June 2026; the letter is public in FDA's warning-letter database
Strengths
- Publishes prices for both compounded medications
- Advertises clinician review and included shipping
- Provides written instructions for canceling before shipment
What to consider
- The refund policy treats charged orders already handed to the carrier as final
- No dispensing pharmacy assignment or state eligibility was verified for an individual order
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.